Abstract:Protein Z-dependent protease inhibitor (ZPI), a serpin family protein, together with its tightly bound vitamin K-dependent protein cofactor, protein Z (PZ), function to rapidly and specifically inhibit membrane-bound FXa. Along with antithrombin, tissue factor pathway inhibitor (TFPI), and activated protein C (APC), the ZPI/PZ complex comprises one of the major endogenous anticoagulants in human plasma. Recent findings showing that ZPI/PZ regulates prothrombinase activity and that ZPI/PZ gene knockout partly restores hemostasis in a hemophilia mouse model have suggested that the neutralization of ZPI/PZ anticoagulant function could provide an alternative therapy for hemophilia treatment. Compared with other alternative therapies currently in development that target APC, TFPI, and antithrombin anticoagulants, anti-ZPI/PZ therapy is expected to be safer and similarly effective. Recent progress in the development of potent, specific ZPI/PZ antagonists should enable testing of this potentially safer therapy in a hemophilia mouse model. *Correspondence to: Department of Periodontics, University of Illinois at Chicago, 801 S. Paulina St., Chicago, IL 60612, USA, E-mail: xinhuang@uic.edu

Protein Z-dependent Protease Inhibitor/protein Z Complex, a New Target for Hemophilia Treatment